Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the virus ent...

Descripción completa

Detalles Bibliográficos
Autores principales: Passariello, Margherita, Gentile, Chiara, Ferrucci, Veronica, Sasso, Emanuele, Vetrei, Cinzia, Fusco, Giovanna, Viscardi, Maurizio, Brandi, Sergio, Cerino, Pellegrino, Zambrano, Nicola, Zollo, Massimo, De Lorenzo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155001/
https://www.ncbi.nlm.nih.gov/pubmed/34040046
http://dx.doi.org/10.1038/s41598-021-90348-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155001/
https://www.ncbi.nlm.nih.gov/pubmed/34040046
http://dx.doi.org/10.1038/s41598-021-90348-7

Ejemplares similares